ABSTRACT
IMPORTANCE Nicotinamide metabolites have recently been implicated in increased risk of major cardiovascular events (MACE). Supportive data about clinical risk of MACE for nicotinamide users is lacking.
OBJECTIVE To determine whether nicotinamide use results in an increase of MACE.
DESIGN, SETTING, PARTICIPANTS Retrospective cohort study of two patient cohorts, Vanderbilt University Medical Center (VUMC) and Military Veteran Program (MVP). The risk of MACE in patients exposed to nicotinamide was compared to the risk of MACE in unexposed patients. In the VUMC cohort, 1228 patients were exposed to nicotinamide based on keyword entry for “nicotinamide” or “niacinamide” and hand-review of charts, while 253 were unexposed but had documented recommendation for use. In the MVP cohort, there were 1594 with exposure to nicotinamide propensity score matched to 2694 without exposure.
EXPOSURES The primary exposure for the VUMC cohort was a confirmed exposure to nicotinamide in chart review. The primary exposure for the MVP cohort was medication entry for “nicotinamide” or “niacinamide”.
MAIN OUTCOME(S) AND MEASURE(S) The primary outcome was development of MACE based on a validated phenotype.
RESULTS Between both cohorts, 6039 patients were included, of whom 5125 were male with a mean age of 63.2 years. Neither cohort had significant differences in mean age, sex, race and ethnicity between the nicotinamide exposed and unexposed groups. In the VUMC cohort, there was no significant association between nicotinamide exposure and the primary outcome of MACE (HR 0.76, 95% CI 0.46 – 1.25, p = 0.28). MACE prior to nicotinamide exposure was strongly associated with subsequent MACE (HR 9.01, 95% CI 5.90 – 13.70, p < 0.001). In the MVP cohort, we adjusted for MACE risk factors as potential confounding variables and saw no significant association between nicotinamide exposure and MACE (HR 1.00 95% CI 0.75 – 1.32), while history of prior MACE remained strongly associated with subsequent MACE (HR 9.50, 95% CI 6.38 – 14.1).
CONCLUSIONS AND RELEVANCE In this retrospective cohort study of 6039 adults from two different patient populations, we found no increased risk of MACE in patients with nicotinamide exposure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by awards IK2 CX002452 (Wheless) and CX002531 (Hartman). Please see Supplementary File 1 for the full MVP Core Acknowledgements. Dr. Hartman is supported by the Department of Defense under award number W81XWH2110819. The project described was supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences, the National Institutes of Health, the Department of Veterans Affairs or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Central Institutional Review Board from the Veterans Administration gave ethical approval of this work as exempt research, and the Institutional Review Board from Vanderbilt University Medical Center gave ethical approval of this work as human subjects research with waiver of consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵13 See supplement for full list of investigators
Conflict of interest: The authors have no conflicts to declare
Study approved as VA IRB 1750541 exempt research and VUMC VR54787 human subjects research with waiver of consent.
Data sharing statement
Individual-level data from both cohorts are access-restricted and cannot be shared
Abbreviations
- 2PY
- N1-methyl-2-pyridone-5-carboxamide
- 4PY
- N1-methyl-4-pyridone-3-carboxamide
- acmsd
- aminocarboxymuconate semialdehyde decarboxylase
- CI
- confidence interval
- CPT
- Current Procedural Terminology
- EHR
- electronic health record
- HR
- hazard ratio
- ICD
- International Classification of Disease
- IRB
- Institutional Review Board
- MACE
- major adverse cardiovascular events
- MVP
- Million Veteran Program
- SD
- Synthetic Derivative
- STROBE
- Strengthening the Reporting of Observational studies in Epidemiology (STROBE)
- VCAM-1
- vascular cell adhesion molecule -1
- VUMC
- Vanderbilt University Medical Center
